3-(甲氧基甲基)苄腈 | 1515-86-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(甲氧基甲基)苄腈
• 英文名称: 3-(methoxymethyl)benzonitrile
• CAS: 1515-86-2
• 化学式: C₉H₉NO
• mdl: MFCD09938201
• 分子量: 147.177
• InChiKey: SMAUAOPCJDOPMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  3-(甲氧基甲基)苄腈 在 镍 甲酸 、 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 55.0h， 生成 5-[[3-(Methoxymethyl)phenyl]methyl]pyrimidine-2,4-diamine
  参考文献：
  名称：

  定量结构-选择性关系。比较5-（取代的苄基）-2,4-二氨基嘧啶对大肠杆菌和牛肝二氢叶酸还原酶的抑制作用。

  摘要：

  在我们以前的出版物中（Blaney，JM； Dietrich，SW； Reynolds，MA； Hansch，CJ Med。Chem。1979，22，614），提出了相关方程式对牛肝和大肠杆菌二氢叶酸还原酶（DHFR）的抑制作用。 5-（取代的苄基）-2,4-二氨基嘧啶。这些方程式揭示了这两种酶与取代基相互作用的方式的差异，这解释了甲氧苄啶等药物的高选择性。我们在本报告中测试并进一步开发了这些方程式。特别令人感兴趣的是，我们先前发布的大肠杆菌DHFR相关方程可准确预测目前在临床上使用的甲氧苄氨嘧啶（tetroxoprim）的商业竞争者的效力。我们认为，可以通过两个相关方程设计甲氧苄啶的新的有效竞争者。

  DOI：

  10.1021/jm00137a012
• 作为产物：
  描述：

  间甲基苯腈 在 chromium(VI) oxide 、 sodium tetrahydroborate 、 水 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 3-(甲氧基甲基)苄腈
  参考文献：
  名称：

  Protonation susceptibility and fragmentation capability of functional groups in chemical ionization mass spectrometry of simple bifunctional compounds. Semi-quantitative interpretation of spectra

  摘要：

  AbstractPositive‐ion, methane‐mediated chemical ionization mass spectra were measured for simple bifunctional aromatic compounds of the type m‐XCH2C6H4CH2Y, where X = NH2 and N(CH3)2, and Y = OH and OCH3. Essentially only three peaks of ions, [MH]+, [MH – XH]+ and [MH – YH]+, have appeared for each compound. Since the two functional groups XCH2– and YCH2– do not interact with each other after protonation or after fragmentation, they are assumed to be protonated and to undergo fragmentations independently. The relative protonation susceptibility and fraction of fragmenting [MH]+ can be estimated for each functional group in these compounds. A semi‐quantitative interpretation of the observed spectra is presented.

  DOI：

  10.1002/oms.1210280203

文献信息

• Efficient Approach to Amide Bond Formation with Nitriles and Peroxides: One-Pot Access to Boronated β-Ketoamides
  作者：Babasaheb Sopan Gore、Gopal Chandru Senadi、Amol Milind Garkhedkar、Jeh-Jeng Wang

  DOI：10.1002/adsc.201700532

  日期：2017.9.4

  An efficient, mild and practical approach for the synthesis of amides from nitriles and peroxides is reported in the presence of boron trifluoride ethereate. In this protocol, we utilized peroxides as C1 synthons for the amidation reaction. Also, we successfully prepared boron‐containing β‐ketoamides in a one‐pot assembly from β‐ketonitriles. A variety of functional groups were tolerated in moderate

  据报道，在三氟化硼醚化物存在下，由腈和过氧化物合成酰胺的有效，温和和实用的方法。在该方案中，我们将过氧化物用作酰胺化反应的C 1合成子。另外，我们还成功地从β-乙腈一锅中制备了含硼的β-酮酰胺。中等至良好的产量可耐受多种官能团。自由基抑制研究表明，反应是通过非自由基途径进行的。
• [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078331A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
• SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150329556A1

  公开（公告）日：2015-11-19

  The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR 1 (R 1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R 2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH 2 ), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

  本发明提供了一种新型酰胺衍生物，具有基质金属蛋白酶抑制活性，并且作为药用剂是有用的，该化合物由以下式(I)表示，其中环A是一个可选择取代的含氮杂环，环B是一个可选择取代的单环同核环或可选择取代的单环杂环，Z是N或NR1（R1是氢原子或可选择取代的碳氢基团），是一个单键或双键，R2是氢原子或可选择取代的碳氢基团，X是一个具有1到6个原子的可选择取代的间隔物，环C是（1）一个可选择取代的同核环或（2）一个除了由（II）表示的环之外的可选择取代的杂环（X′是S、O、SO或CH2），并且环B和环C中至少有一个有取代基，但不包括N-(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]2-羟基丙基}5,6-二甲基-4-氧代-1,4-二氢噻唑并[2,3-d]嘧啶-2-羧酰胺，或其盐。
• 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE
  申请人：Horiuchi Yoshihiro

  公开号：US20120225876A1

  公开（公告）日：2012-09-06

  Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R 1a and R 1b may be the same or different and each independently represents a C 1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X 1 represents a hydroxyl group or an aminocarbonyl group; Z 1 represents a single bond or the like; and R 2 represents an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group or the like.)

  公开了一种由公式(1)表示的化合物或其药理可接受的盐(在公式中，A代表由公式(A-1)表示的基团；R1a和R1b可以相同或不同，每个独立地表示一个可以由一个到三个卤素原子取代的C1-6烷基；m和n各自独立地表示0-5之间的整数；X1代表羟基或氨基甲酰基；Z1代表单键等；R2代表一个可选地取代的C1-6烷基，一个可选地取代的C6-10芳基等)。
• PYRROLIDINYL SULFONE RORGAMMA MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191483A1

  公开（公告）日：2015-07-09

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ活性的方法和治疗受疾病或紊乱困扰的主体中是有用的，例如，主体将从调节RORγ活性中获益的自免疫和/或炎症紊乱。